Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• High-grade B-cell lymphomas (HGBCLs) represent a heterogeneous group of aggressive lymphoid neoplasms.
• Subtypes include diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and intermediate entities.
• Morphologic similarity can mask diverse clinical behaviors and treatment responses.

Purpose of the Study:

• To review established and emerging biomarkers for high-grade B-cell lymphomas.
• To emphasize the importance of integrated diagnostic approaches beyond morphology.
• To guide clinical management and therapeutic strategies for HGBCLs.

Main Methods:

• Review of established and emerging biomarkers relevant to HGBCL clinical management.
• Discussion of genetic and immunophenotypic work-up complementing morphologic evaluation.
• Synthesis of current literature on diagnostic modalities for HGBCL stratification.

Main Results:

• Morphologic assessment alone is insufficient for accurate HGBCL classification.
• Genetic and immunophenotypic analyses are essential for comprehensive stratification.
• Biomarkers play a critical role in determining prognosis and guiding therapy.

Conclusions:

• Integrated diagnostic work-up, including biomarkers, is vital for managing HGBCLs.
• Accurate stratification based on comprehensive analysis improves patient outcomes.
• Further research into novel biomarkers will enhance precision medicine for HGBCLs.